{
  "docId": "019dd923-622b-71dc-a6dc-b34895e14e2f",
  "docSlug": "3d2fbe2d392f",
  "documentTitle": "Elanco Animal Health (ELAN)",
  "authorId": "21_Ancora",
  "authorName": "Ancora",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 36,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 9,
  "notes": "Uses CEO quotes to highlight the gap between management's acquisition thesis and actual financial performance.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "kpi_table",
    "callout_box",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6dc-b34895e14e2f/25",
  "deckHref": "/decks/019dd923-622b-71dc-a6dc-b34895e14e2f",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6dc-b34895e14e2f.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6dc-b34895e14e2f#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "callout",
      "text": "The Bayer acquisition has weakened Elanco’s financial position.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c10f383-7f0d-4d0f-9ea7-f8dd4881d54f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Operating Cash Flow: $271",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-fb91-749f-a6b7-9b8d6d76fe42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.94,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Elanco’s free cash flow profile has been significantly impacted by the Bayer acquisition. The Company spent ~$650 million on project costs related to the integration of the business, EBITDA has actually declined since 2021, cash interest expense has increased significantly and net working capital has become a meaningful drag.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e3842e8-e816-4e4f-90f6-3d117a5c19d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.28
      },
      "kind": "quote",
      "text": "Importantly, we'll have strong cash flow generation as a result of this transaction, about $1 billion in operating cash flow in the second year and accelerating....",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eaa95427-5e5b-4063-a10c-9ba50f97305c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.68
      },
      "kind": "quote",
      "text": "Looking at our returns, Elanco will generate significant cash flow and exercise strong cash management to pay down debt, reducing interest cost as quickly as possible, increasing optionality of the business and most importantly delivering double digit EPS growth to unlock value for you, our shareholders.",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe935e1e-3f39-41fb-ba31-499cf1aa57da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"Importantly, we'll have strong cash flow generation as a result of this transaction, about $1 billion in operating cash flow in the second year and accelerating....\" — Acquisition of Bayer by Elanco 8/20/2019; \"Looking at our returns, Elanco will generate significant cash flow and exercise strong cash management to pay down debt, reducing interest cost as quickly as possible, increasing optionality of the business and most importantly delivering double digit EPS growth to unlock value for you, our shareholders.\" — Elanco 2020 Investor Day 12/15/2020",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd952-fb91-749f-a6b7-9527cfc2b378",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.01,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Ancora, Company filings.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebed559a-49d6-429e-96ae-55f69747d0fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.05,
        "y": 0.33
      },
      "kind": "table",
      "text": "Factors Impacting Elanco Operating Cash Flow ($mm)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "393d5d68-9a32-4db2-b2c3-149dac3d94df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Elanco’s Botched Bayer Acquisition Integration Has Failed to Generate Cash Flow",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "006e298f-ff48-4700-bec3-687c2e734526",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "bcf04020-7105-45f3-9526-e62ca2d0fdcf",
      "evidence": "Contrasting CEO quotes with actual financial data table",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 28,
      "from": 25,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5f54024-1603-47af-b595-6ef1dd70c066",
      "evidence": "The document stresses the consequences of ignoring shareholder concerns.",
      "position": 1,
      "objective": "Emphasize the cost of inaction and ignoring shareholder concerns.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}